Blar i forfatter "Tvedt, Tor Henrik Anderson"

Viser treff 1-2 av 2

    • Early response evaluation by single cell signaling profiling in acute myeloid leukemia 

      Tislevoll, Benedicte Sjo; Hellesøy, Monica; Fagerholt, Oda Helen Eck; Gullaksen, Stein-Erik; Srivastava, Aashish; Birkeland, Even; Kleftogiannis, Dimitrios; Ayuda Duran, Pilar; Piechaczyk, Laure Isabelle; Tadele, Dagim Shiferaw; Skavland, Jørn; Panagiotis, Baliakas; Hovland, Randi; Andresen, Vibeke; Seternes, Ole Morten; Tvedt, Tor Henrik Anderson; Aghaeepour, Nima; Gavasso, Sonia; Porkka, Kimmo; Jonassen, Inge; Fløisand, Yngvar; Enserink, Jorrit; Blaser, Nello; Gjertsen, Bjørn Tore (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-01-07)
      Aberrant pro-survival signaling is a hallmark of cancer cells, but the response to chemotherapy is poorly understood. In this study, we investigate the initial signaling response to standard induction chemotherapy in a cohort of 32 acute myeloid leukemia (AML) patients, using 36-dimensional mass cytometry. Through supervised and unsupervised machine learning approaches, we find that reduction of ...

    • VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study 

      Nørgaard, Jakob Nordberg; Moore, Kari Lenita Falck; Slørdahl, Tobias Schmidt; Vik, Anders; Tvedt, Tor Henrik Anderson; Schjesvold, Fredrik (Journal article; Tidsskriftartikkel; Peer reviewed, 2024-04-09)
      Induction therapy followed by autologous stem cell transplantation (ASCT) is standard of care for young and fit patients with newly diagnosed multiple myeloma (MM) [1]. Induction therapy has evolved from doublet to triplet to quadruplet regimens over the last decades. The most common triplet therapy is either Bortezomib-Cyclophosphamide-Dexamethasone (VCD), Bortezomib-Lenalidomide-Dexamethasone ...